[HTML][HTML] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib
TJ Lynch, DW Bell, R Sordella… - … England Journal of …, 2004 - Mass Medical Soc
Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). …
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). …
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak, R Sordella, DW Bell… - Proceedings of the …, 2005 - National Acad Sciences
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the
epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to …
epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to …
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell, I Gore, RA Okimoto, N Godin-Heymann… - Nature …, 2005 - nature.com
Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that
respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific …
respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific …
An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor
…, WL Gerald, SO Vargas, L Chin, AJ Iafrate, DW Bell… - Science, 2007 - science.org
Wilms tumor is a pediatric kidney cancer associated with inactivation of the WT1 tumor-suppressor
gene in 5 to 10% of cases. Using a high-resolution screen for DNA copy-number …
gene in 5 to 10% of cases. Using a high-resolution screen for DNA copy-number …
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
…, DP Ryan, JW Clark, DC Sgroi, DA Haber, DW Bell - Clinical Cancer …, 2006 - AACR
Purpose: Specific activating mutations within the epidermal growth factor receptor (EGFR)
identify a subset of non–small cell lung cancers with dramatic sensitivity to the specific tyrosine …
identify a subset of non–small cell lung cancers with dramatic sensitivity to the specific tyrosine …
Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell, TJ Lynch, SM Haserlat, PL Harris… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but …
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but …
Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms
DW Bell, BW Brannigan, K Matsuo, DM Finkelstein… - Clinical cancer …, 2008 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) gene occur in a
subset of non–small-cell lung cancer (NSCLC) and are highly predictive of the clinical …
subset of non–small-cell lung cancer (NSCLC) and are highly predictive of the clinical …
Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR
Purpose: Small-molecule tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) have shown modest yet reproducible response rates in patients with squamous …
(EGFR) have shown modest yet reproducible response rates in patients with squamous …
Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin
Mutational inactivation of genes controlling the DNA-damage response contributes to
cancer susceptibility within families and within the general population as well as to sporadic …
cancer susceptibility within families and within the general population as well as to sporadic …
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib
…, M Moscato, BW Brannigan, A Morabito, DW Bell… - Lung Cancer, 2008 - Elsevier
We describe two non-small-cell lung cancer (NSCLC) patients in which treatment with the
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a …